Planned Sale Of China’s Cedara Medical Software Firm Canceled
This article was originally published in PharmAsia News
Executive Summary
U.S.-based Merge Healthcare has canceled plans to sell its Chinese subsidiary, Cedara Software Shanghai to Inqgen Technology of Taiwan. Merge, which produces medical-imaging software for drug and device makers, has changed management since the sale was announced nearly a year ago. The new executives consider China as a major factor in the growth planned for its core business, an official said. He said Cedara would enable Merge to have sales, marketing, customer support and engineering presences in China, potentially the world's largest market for its products. (Click here for more